Tracers / [177Lu]Lu-BCY18469
[177Lu]Lu-BCY18469
Also written as [Lu-177]Lu-BCY18469
- Radionuclide
- Lu-177 t½ 9584.6 min
- Modality
- Therapy
- Production route
- —
- Stage
- preclinical study
- Syntheses indexed
- 1
What it is
- Compound class
- EphA2-targeting bicyclic peptide (Bicycle®)
- Target / mechanism
- EphA2 (erythropoietin-producing hepatocellular receptor A2) PMID 39239524
- Clinical application
- —
- Theranostic pair
- —
Regulatory status
- FDA
- —
- EMA (centralised)
- —
- Other approvals
- —
- Brand names
- —
Clinical use
- Typical injected activity
- —
- Uptake time
- —
Reported in the literature. Not a dosing recommendation.
Published syntheses
| Module | Cassette | Purification | Yield % | RCP % | Precursor / supplier | Source |
|---|---|---|---|---|---|---|
| Manual synthesis | — | none | — | ≥98% | BCY18469 | 39239524 2024 Theranostics radiolabeling with 177Lu was performed by mixing 50 µL of NH4OAc buffer |
Need this precursor?We can point you to suppliers for [177Lu]Lu-BCY18469, or handle the enquiry for you.
Get in touchNotes
Added at stage 22: promoted from 'Reported once' (single-article, no diagnostic pair at discovery) because a full-text synthesis with extracted data exists in parsed-therapy.xlsx -- PMID(s): 39239524. Target/mechanism, clinical application, indications, approval and precursor fields still need per-agent research and are intentionally left empty. Compound class inferred from precursor name (not stated outright) -- PMID 39239524: 'BCY18469 and BCY26443 were synthesized using solid phase peptide synthesis'. Stage set/updated at stage 23 from PMID 39239524: 'This study presents the development and comprehensive in vitro and in vivo preclinical evaluation of BCY18469, a novel EphA2-targeting bicyclic peptide-based radiotheranostic agent.'.